Abstract

You have accessJournal of UrologyCME1 Apr 2023MP33-11 P16 STATUS IS AN INDEPENDENT PREDICTOR OF OVERALL SURVIVAL IN METASTATIC PENILE CANCER IN A LARGE CONTEMPORARY COHORT James Churchill, Ashwin Sachdeva, Craig Jones, Allaudin Issa, Christian Fankhauser, Andrew Hudson, Anna Tran, Pedro Oliveira, Helen Johnson, Maurice Lau, Arie Parnham, and Vijay Sangar James ChurchillJames Churchill More articles by this author , Ashwin SachdevaAshwin Sachdeva More articles by this author , Craig JonesCraig Jones More articles by this author , Allaudin IssaAllaudin Issa More articles by this author , Christian FankhauserChristian Fankhauser More articles by this author , Andrew HudsonAndrew Hudson More articles by this author , Anna TranAnna Tran More articles by this author , Pedro OliveiraPedro Oliveira More articles by this author , Helen JohnsonHelen Johnson More articles by this author , Maurice LauMaurice Lau More articles by this author , Arie ParnhamArie Parnham More articles by this author , and Vijay SangarVijay Sangar More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003266.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Penile squamous cell carcinoma (PSCC) is rare and there is a need to refine selection of patients for optimal management. Human papilloma virus infection is a known PSCC risk factor, measured by the histopathological presence of the p16 protein. This study has examined effect of p16 status on overall survival (OS) of PSCC patients managed at a tertiary referral centre. METHODS: We analysed retrospective data from a prospectively maintained database for patients with PSCC treated between 2003 and 2022. We excluded patients without reported p16 status. TNM stage was defined by histopathology (AJCC v8) except where fixed inguinal nodes (cN3), pelvic lymphadenopathy (cN3) or distant metastatic disease (M1) were present without histopathological confirmation. The primary outcome was OS (time from definitive primary surgery to death, censored for last follow-up). Multivariate Cox regression analysis for age, p16 status, TNM-stage and grade was performed. Audit approval was obtained. RESULTS: We identified 470 eligible patients. Median follow-up was 28 months (range 0-265). 118 patients (25%) did not undergo invasive lymph node staging (pNX). For the whole cohort, p16+ patients demonstrated 10% greater 5-year OS compared to p16- (71% versus 61%; Figure 1). After multivariate analysis (Table 1), there remained a significant difference in OS with 40% reduction in the risk of death for p16+ patients compared to p16-. On exploratory analysis by stage, only the N1 group retained this difference, suggesting that this is the group where p16 status may be of most clinical impact. CONCLUSIONS: Our data demonstrate that p16+ predicts for improved OS compared to p16- status in PSCC patients. After adjusting for age, stage and grade, this difference was retained in patients with N1 disease, suggesting that p16 status could be further explored as a predictive biomarker in this group. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e454 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information James Churchill More articles by this author Ashwin Sachdeva More articles by this author Craig Jones More articles by this author Allaudin Issa More articles by this author Christian Fankhauser More articles by this author Andrew Hudson More articles by this author Anna Tran More articles by this author Pedro Oliveira More articles by this author Helen Johnson More articles by this author Maurice Lau More articles by this author Arie Parnham More articles by this author Vijay Sangar More articles by this author Expand All Advertisement PDF downloadLoading ...

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.